Please assess the completion status of the following clinical trial:

Trial Title: Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Untunneled CVC inserted in the internal jugular or femoral vein within the past 24 hours~2. Child anticipated to stay in the pediatric intensive care unit ≥48 hours~3. CVC anticipated to be required for ≥24 hours~4. \>36 weeks corrected gestational age to \<18 years old~Exclusion Criteria~1. Coagulopathy (i.e., international normalized ratio \>2.0, activated partial thromboplastin time \>50 seconds or platelet count \<50,000/mm3)~2. Known bleeding disorder~3. Clinically relevant bleeding as defined by the International Society on Thrombosis and Hemostasis (i.e., Hb decreased ≥2 g/dl in 24 hours, required medical or surgical intervention to restore hemostasis, or in a critical organ system \[i.e., retroperitoneum, pulmonary, intracranial or central nervous system\])~4. \<60 days from a clinically relevant bleeding as defined above~5. \<7 days after trauma or surgery~6. Anticipated surgery within 48 hours after insertion of the CVC~7. Renal failure (i.e., creatinine clearance \<30 mL/min)~8. Presence of epidural catheter~9. Currently taking an antithrombotic agent (e.g., low molecular weight heparin (LMWH), unfractionated heparin (UFH) at therapeutic doses, Coumadin or aspirin)~10. Radiologically documented DVT at the site of insertion of the CVC in the previous 6 weeks~11. Known hypersensitivity to heparin or its components, including pork products~12. History of heparin-induced thrombocytopenia (HIT) (i.e., positive serotonin release assay)~13. Currently pregnant~14. Currently lactating~15. Prior enrollment in the study~16. Limitation of care

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis with enoxaparin (Type: EXPERIMENTAL): A clinical nurse will administer enoxaparin subcutaneously \<24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
- Control arm (Type: NO_INTERVENTION): Participants randomized to the control arm will receive no 'placebo' intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).